WQ3.F INNO-GENE SA ZY -10
- Market cap
- EUR 18.3M
- P/E
- 19.0x
- P/B
- 3.09x
- ROE
- -6.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2025.
Is WQ3.F undervalued?
Graham numberWQ3.F trades 61.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INNO-GENE SA ZY -10 fundamental analysis
No fundamental analysis for INNO-GENE SA ZY -10 yet.
INNO-GENE SA ZY -10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INNO-GENE SA ZY -10
HyEnergy S.A. provides genetic diagnostic solutions in Poland. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of solid tumors. In addition, it provides DNA analysis and genetic diseases diagnostic service based on NGS technology. HyEnergy S.A. was formerly known as Inno-Gene S.A. and changed its name to HyEnergy S.A. in October 2024. The company was incorporated in 2010 and is headquartered in Warsaw, Poland.
Full company profileINNO-GENE SA ZY -10 financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
INNO-GENE SA ZY -10 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 29.9M | 16.4M | 1.13M | 3.30M | 290K |
| Gross Profit | 22.5M | 13.6M | 443K | 3.29M | 282K |
| Operating Income | 10.6M | -910K | -2.52M | 1.59M | -1.06M |
| EBITDA | 8.71M | 874K | -2.37M | 191K | -718K |
| Net Income | 6.03M | 315K | -6.22M | 18.8K | -1.13M |
| EPS | 1.06 | 0.06 | -1.09 | 0.00 | -0.03 |
| Balance Sheet | |||||
| Total Assets | 13.4M | 10.3M | 5.60M | 14.9M | 25.0M |
| Total Liabilities | 5.60M | 2.22M | 3.16M | 6.62M | 7.45M |
| Shareholders' Equity | 7.85M | 8.05M | 2.44M | 8.27M | 17.5M |
| Cash & Short-term Investments | 3.92M | 153K | 281K | 259K | - |
| Cash Flow | |||||
| Operating Cash Flow | 6.75M | 11.0K | -2.49M | -380K | -10.0K |
| Capital Expenditure | 82.0K | 0.00 | 0.00 | 45.0K | 1.30M |
| Free Cash Flow | 6.67M | 11.0K | -2.49M | -1.18M | -1.31M |
| Ratios | |||||
| ROE | 76.9% | 3.9% | -255.1% | 0.2% | -6.5% |
| ROA | 44.9% | 3.1% | -111.2% | 0.1% | -4.5% |
| Net Profit Margin | 20.1% | 1.9% | -551.4% | 0.6% | -390.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
INNO-GENE SA ZY -10 dividends
INNO-GENE SA ZY -10 has not paid dividends in the last 6 fiscal years.
Who owns INNO-GENE SA ZY -10
- Insiders 63.47%
- Institutions 0.00%
- Public & others 36.53%
- Shares outstanding 33.6M
- Free float 10.5M
INNO-GENE SA ZY -10 company profile
- Company name
- INNO-GENE SA ZY -10
- Ticker
- WQ3.F
- ISIN
- PLINNGN00015
- Exchange
- Frankfurt Exchange
- Sector
- Basic Materials
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- Jana Pawla II 22, Warsaw, Poland, 00-133
- Phone
- 48 509 65 80 06
- Website
- inno-gene.pl
About INNO-GENE SA ZY -10
HyEnergy S.A. provides genetic diagnostic solutions in Poland. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of solid tumors. In addition, it provides DNA analysis and genetic diseases diagnostic service based on NGS technology. HyEnergy S.A. was formerly known as Inno-Gene S.A. and changed its name to HyEnergy S.A. in October 2024. The company was incorporated in 2010 and is headquartered in Warsaw, Poland.
INNO-GENE SA ZY -10 management
1- Mr. Jacek Marek WojciechowiczPresident of the Management Board